RA Capital Management L.P. Has $40.69 Million Stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

RA Capital Management L.P. cut its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 20.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,866,400 shares of the company's stock after selling 466,600 shares during the period. RA Capital Management L.P. owned 6.31% of Dianthus Therapeutics worth $40,688,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. R Squared Ltd bought a new position in Dianthus Therapeutics during the fourth quarter valued at about $26,000. KLP Kapitalforvaltning AS bought a new stake in shares of Dianthus Therapeutics during the 4th quarter worth about $33,000. KBC Group NV acquired a new position in Dianthus Therapeutics in the 4th quarter valued at $35,000. AlphaQuest LLC grew its holdings in Dianthus Therapeutics by 273.1% in the 4th quarter. AlphaQuest LLC now owns 4,197 shares of the company's stock valued at $91,000 after buying an additional 3,072 shares during the last quarter. Finally, Intech Investment Management LLC bought a new position in shares of Dianthus Therapeutics during the 4th quarter worth about $201,000. 47.53% of the stock is currently owned by institutional investors.

Dianthus Therapeutics Stock Down 7.0 %

Shares of NASDAQ:DNTH traded down $1.51 during midday trading on Tuesday, reaching $20.05. The company had a trading volume of 169,712 shares, compared to its average volume of 318,005. The business's 50 day moving average price is $19.87 and its 200 day moving average price is $22.59. The stock has a market cap of $643.97 million, a PE ratio of -8.02 and a beta of 1.48. Dianthus Therapeutics, Inc. has a 1-year low of $13.36 and a 1-year high of $32.27.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, topping analysts' consensus estimates of ($0.85) by $0.04. The business had revenue of $1.33 million for the quarter, compared to analyst estimates of $1.40 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. On average, research analysts expect that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

DNTH has been the subject of a number of analyst reports. Guggenheim restated a "buy" rating and set a $84.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. HC Wainwright reissued a "buy" rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Finally, Wedbush reiterated an "outperform" rating and set a $36.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $54.33.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.